Avenue Therapeutics announces publication of preclinical data of BAER-101

Avenue Therapeutics announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg model of absence epilepsy. Data published showcase BAER-101’s ability to selectively target GABAA alpha2 and alpha3 subtypes more than alpha1 and alpha5, potentially improving anti-convulsant and anxiolytic activity while minimizing the risk of tolerance and abuse associated with existing treatments in this drug class. The publication describes the extent of anti-seizure activity of BAER-101 in the GAERS model, a widely used and translationally relevant animal model. The study demonstrated full suppression of seizure activity with a minimal effective dose of 0.3 mg/kg. The effect of BAER-101 was fast in onset and stable throughout the duration of testing. Results from the testing showed that the number of spike-wave discharges were dose-dependently reduced by BAER-101, and no adverse safety events were observed up to a dose 300x the MED.